Docket No. CEN298USANP



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on

October 10, 2003
(Date of Deposit)

Kirk Baumeister

(Name of applicant, assignee, or Registered Representative)

October 10, 2003

(Date of Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Lamine Mbow

Patrick Branigan Jill Giles-Komar Linda Snyder George Heavner

Serial No.: 10/600,348 Art Unit: 1645

Filed: June 20, 2003 Examiner:

For : METHOD FOR GENERATING MONOCLONAL ANTIBODIES

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

In ac	ccordance with §1.129(a), this Information
Disclosure Stat	ement is being filed in connection with \square the
first or 🗌 seco	nd After Final Submission, therefore:
	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/CEN298USANP/KB the fee of $$180.00$ as set
	forth in §1.17(p).

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

		Statement in Accordance with §1.97(e)
		(attached); or
		Please charge Deposit Account No. 10-
		0750/CEN298USANP/KB the fee of \$180.00 as set
		forth in §1.17(p).
either a	e Stat Final	ecordance with §1.97(d), this Information tement is being filed after the mailing date of Action under §1.113 or a Notice of Allowance but before the payment of the Issue Fee.
		ereby petition(s) for consideration of this
Informati Accordanc	on Dis	sclosure Statement. Included are: Statement in §1.97(e) as set forth below and the fee of forth in §1.17(p).
⊠ attached	-	es of each of the references listed on the PTO-1449 are enclosed herewith.
1449 are	_	es of references listed on the attached Form PTC sed herewith EXCEPT THAT:
		In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
English :		e are no listed references which are not in the ge.

The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN298USANP/KB. This form is submitted in triplicate. Respectfully submitted, KIRK BAUMEISTER Reg. No. 33,833 Attorney for Applicants Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: October 10, 2003



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

nu to a collection of information unless it displays a valid own control furtiber.			
Application Number	10/600,348		
Filing Date	June 20, 2003		
First Named Inventor	M. Lamine Mbow		
Group Art Unit	1645		
Examiner Name			
Attorney Docket Number	CEN298USANP		

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code of Cited Document where relevant passages Examiner of Cited Document or relevant figures appear (if known) Number mm-dd-yyyy No.1 11-23-1993 5,264,209 Mikayama et al

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Date of Publication Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant Тę Examiner Cite mm-dd-yyyy Applicant of Cited Document figures appear KindCode5 Office³ Number⁴ No.1


Examiner	Date	
	Considered	
Signature	Conductor	and the second s

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington,

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

ond to a collection of information unless it displays a valid Chilb control number.			
Application Number	10/600,348		
Filing Date	June 20, 2003		
First Named Inventor	M. Lamine Mbow		
Group Art Unit	1645		
Examiner Name			
Attorney Docket Number	CEN298USANP		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		REINER ET AL, "The regulation of Immunity to Leishmania Major," Rev. Immunol., 1995, page 151, VOL. 13.	
		FINKELMAN ET AL, "Lymphokine Control of In Vivo Immunoglobulin Isotype Selection,"I," Annu. Rev. Immunol., 1990, page 303., VOL. 8.	
		PEPINSKY, "Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-β-1a with Preserved Vitro Bioactivity," J. Pharm Exp. Ther., 2001, page 1059, VOL. 297.	
		COHEN, "Modulating the immune response to genetic immunization," Faseb J.,1998, page 1611, VOL. 12.	
·		ROBINSON, "DNA Vaccines: Basic mechanism and immune responses (Review)," J. Mol. Med, 1999, page 549, VOL. 4.	
		DONNELLY ET AL., "DNA Vaccines," Dev. Biol. Stand, 1998, page 43, VOL. 95.	
		CASARES ET AL., "Antigen Presentation by Dendtritic Cells after Immunization with DNA Encloding a Major Histocompatibility Complex Class II-restricted Viral Epitope," J. Exp. Med., 1997, page 1481, VOL. 186.	
		AKBARI ET AL, "DNA VACCINATION: Transfection and Activation of Dendritic Cells as Key Events for Immunity," J. Exp. Med, 1999, page 169, VOL. 189.	
		YOU ET AL, "Targeting Dendritic Cells to enhance DNA Vaccine Potency," Cancer Research, 2001, page 3704, VOL. 61.	
		WYSOCKA ET AL, "Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice," EUR. J. IMMUNOL. ,1995, page 672, VOL. 25.	
		MORI ET AL, "IL-4 Promotes the Migration of Circulating B Cells to the Spleen and Increases Splenic B Cell Survival," J. Immunol., 2000, page 5704, VOL. 164.	
		ICHIKAWA ET AL, "Anti-II-12 antibody prevents the development and progression of multiple scleroisis-like relapsing- remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide," Journal of Neuroimmunology, 2000, page 56, VOL. 102.	
		SMITH ET AL, "Th1 and Th2 CD4* T Cells Provide Help for B Cell Clonal Expansion and Antibody Synthesis in a Similar Manner In Vivo," 2000, page 3136, VOL. 165.	
		LI ET AL, "Plasmid DNA Encoding the Respiratory Syncytial Virus G Protein Is a Promising Vaccine Candidate," Virology, 2000, page 54, VOL. 269.	
			-
	1		
	—		<u> </u>
	+		
			<u> </u>

Examiner	Date	
Signature	Considered	
Signature		